Relief Right Where It Hurts
Introducing Tolcylen® Transdermal CBD/CBG Cream — a pharmaceutical-grade, non-psychoactive option for chronic foot pain, arthritis, and neuropathy.
Foot pain is relentless. Whether it’s the first-step agony of plantar fasciitis, the constant ache of arthritic toe joints, the burning numbness of peripheral neuropathy, or the inflammation of tendons that just won’t settle — foot pain colors every moment of your day. At Grants Pass Podiatry, we’re always looking for evidence-informed tools to add to your care plan. That’s why we’re proud to offer Tolcylen® Transdermal CBD/CBG Cream as part of our comprehensive pain management approach.
Unlike generic hemp products sold at retail stores, Tolcylen is a pharmaceutical-grade cream developed by Marlinz Pharma and formulated with the same research-driven standards as their clinically proven antifungal line. It’s manufactured to deliver cannabinoids where other topical products fail: deep into the skin layers where your pain receptors actually live.
What Are CBD and CBG — And Why Does It Matter for Your Feet?
CBD (cannabidiol) and CBG (cannabigerol) are non-psychoactive cannabinoids derived from hemp. They do not produce a “high,” do not contain THC, and are not controlled substances. What they do contain are well-studied properties: anti-inflammatory signaling, pain modulation, and nerve-calming effects — all mediated through receptors in your own body’s endocannabinoid system (ECS).
Your skin, muscles, and nerves are loaded with CB1 and CB2 receptors — the molecular targets that cannabinoids bind to. When applied topically, CBD and CBG interact with these receptors locally, modulating inflammation and pain signals without entering the bloodstream in meaningful amounts. That’s the appeal: targeted relief at the exact site of your pain, with no systemic side effects.
CBG, in particular, is sometimes called the “mother cannabinoid” — it is the precursor molecule from which other cannabinoids are synthesized. When CBD and CBG are combined, as they are in Tolcylen, the therapeutic effect is noticeably stronger than either compound alone: CBD boosts your body’s own endocannabinoids while CBG prevents their breakdown, extending and amplifying the relief.
Why Tolcylen — Not Just Any CBD Cream
The CBD/CBG market is flooded with products that simply don’t work. The reason is almost always the same: poor penetration. The outer layer of your skin — especially on your feet, which has the thickest epidermis of anywhere on your body — is an exceptional barrier. Most over-the-counter creams sit on the surface, never reaching the deeper tissue where your pain originates.
Tolcylen solves this with its patented Tolcylen Delivery Vehicle, a proprietary formulation of five ingredients engineered to carry active compounds through all five layers of the skin and into the dermis. This is the same delivery platform that underpins the brand’s clinically proven antifungal line, which has achieved over 90% patient satisfaction in nail improvement studies.
It uses medical-grade, CO²-extracted, hemp-derived CBD and CBG isolates — certified for potency and guaranteed THC-free by independent third-party laboratory testing on every batch.
Additional advantages: no menthol, camphor, or fragrance that can irritate sensitive skin; no residue or stickiness; and a formulation stable for over five years without separation or degradation.
Where We Use It: Foot Conditions and Mechanisms
At Grants Pass Podiatry, Tolcylen CBD/CBG cream is a complementary tool we incorporate into comprehensive care plans for a range of common, painful foot conditions:
| Condition | How CD / CBG May Help |
|---|---|
| Chronic foot pain | Targets CB1/CB2 receptors to interrupt pain signal transmission; reduces cytokine-driven inflammation at the site |
| Arthritis pain | Anti-inflammatory action reduces joint swelling, stiffness, and pain; clinical data show meaningful pain score improvements in OA and RA models |
| Peripheral neuropathy | CBD modulates TRPV1 channels and CB2 receptors to reduce burning, sharp, and "electric" pain sensations in nerve-damaged tissue |
| Plantar fasciitis | Localized anti-inflammatory effect reduces fascial inflammation, supporting other therapies during the most painful early weeks |
| Tendonitis / bursitis | Reduces peritendinous and bursal inflammation without systemic NSAID side effects |
What the Research Shows
While Tolcylen itself is a proprietary product without published RCT data specific to the formulation, the cannabinoids it delivers — CBD and CBG — are the subject of a growing body of peer-reviewed research:
PHARMACEUTICALS (MDPI), 2024 — SYSTEMATIC REVIEW OF CBD IN PAIN TREATMENT (PUBMED)
A comprehensive systematic review of 40 clinical and preclinical studies, conducted per PRISMA guidelines and published in October 2024, concluded that CBD demonstrates analgesic and anti-inflammatory properties with evidence of effectiveness in reducing pain, particularly in osteoarthritis and chronic pain conditions. The review identified TRPV-1 receptor activation, 5HT-1A modulation, and allosteric CB1 modulation as key mechanisms — all of which are relevant to the foot pain conditions we treat.
PAIN MANAGEMENT NURSING, 2024 — SYSTEMATIC REVIEW OF CBD FOR CHRONIC PAIN (PUBMED)
A 2024 systematic review published in Pain Management Nursing, covering studies through 2023, synthesized evidence that CBD may be useful in managing chronic pain. The review identified anti-inflammatory and analgesic mechanisms, and noted CBD’s potential as a complementary option for patients seeking non-opioid pain management strategies.
SCIENTIFIC REPORTS (NATURE), 2024 — TRANSDERMAL CBD FOR OSTEOARTHRITIS
An open-label feasibility trial published in Scientific Reports (2024) had participants with active hand osteoarthritis apply a transdermal CBD gel three times daily for four weeks. Researchers tracked daily pain scores, grip strength, sleep quality, stiffness, and anxiety. The study found clinically meaningful improvements in pain scores on a 0–10 numeric scale alongside improved grip strength and quality of life measures — providing direct evidence for the feasibility and potential effectiveness of transdermal CBD in an arthritis population.
MEDICAL CANNABIS AND CANNABINOIDS, 2025 — TRANSDERMAL CANNABIS FOR DIABETIC NEUROPATHY (PMC/NCBI)
A Phase III, double-blind, placebo-controlled randomized clinical trial published in 2025 evaluated transdermal cannabinoid formulation over 12 weeks in 100 patients with painful diabetic peripheral neuropathy of the lower extremities. The study found statistically significant improvements in neuropathic pain symptoms in the treatment group compared to placebo, supporting the use of transdermal cannabinoid delivery specifically for neuropathic pain in the feet and lower legs — the patient population we most commonly see in our clinic.
NEUROPATHIC PAIN (PUBMED)
A June 2025 systematic review in Biomolecules analyzed 22 randomized controlled trials of cannabis-based medicines for neuropathic pain (January 2003 through December 2024) and found that CBD-containing formulations demonstrate meaningful activity in modulating neuropathic pain pathways, reinforcing the therapeutic rationale for cannabinoid use in conditions like peripheral neuropathy and diabetic foot pain.
A Note on the Science
Topical CBD and CBG are not FDA-approved drugs, and no topical cannabinoid product is currently approved to diagnose, treat, cure, or prevent any disease. The research cited here reflects emerging and promising evidence from clinical and preclinical studies of topical/transdermal cannabinoids broadly — not studies of the Tolcylen product specifically. As with any new therapy, we recommend discussing this option with your podiatrist before use, particularly if you take other medications. These statements have not been evaluated by the FDA.
How We Use It at Grants Pass Podiatry
Tolcylen CBD/CBG Cream is available directly through our office — you won’t find our pharmaceutical-grade formulation on retail shelves. We incorporate it as part of a comprehensive, individualized treatment plan alongside our other clinical and procedural offerings.
For best results, we guide patients on proper application:
Wash and dry the treatment area thoroughly before applying
Apply a generous amount to cover the entire area of pain
Massage in gently for 45–60 seconds to maximize dermal absorption
Apply 2–4 times daily as directed — effects are cumulative and build over consistent use
Combine with other modalities (orthotics, shockwave therapy, physical therapy) for best outcomes
It’s non-addictive, non-sedating, and has no known interaction with your organs — but as with any treatment, please let us know all medications you’re taking, as cannabinoids may interact with certain drugs even when applied topically. We’ll review your health history before recommending it as part of your plan.
Tired of Foot Pain That Won’t Quit?
Ask us whether Tolcylen CBD/CBG Cream belongs in your treatment plan. We’ll evaluate your condition and build a comprehensive approach that goes beyond the symptom to address the cause.
(541) 476-4458 — Call Us Today
Grants Pass Podiatry · Serving Southern Oregon
SCIENTIFIC REFERENCES
Cásedas G, de Yarza-Sancho M, López V. Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals (Basel). 2024 Oct 28;17(11):1438. doi:10.3390/ph17111438
Mohammed SYM, Leis K, Mercado RE, et al. Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain Manag Nurs. 2024 Apr;25(2):e76–e86. doi:10.1016/j.pmn.2023.10.002
Bawa Z, Lewis D, Gavin PD, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep. 2024;14:11792. doi:10.1038/s41598-024-62428-x
Seevathee K, Kessomboon P, Manimmanakorn N, et al. Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities. Med Cannabis Cannabinoids. 2025;8(1):1–14. doi:10.1159/000542511
Almuntashiri N, El Sharazly BM, Carter WG. Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review. Biomolecules. 2025 Jun 4;15(6):816. doi:10.3390/biom15060816
Grants Pass Podiatry · Grants Pass, Oregon · This content is for educational purposes only and does not constitute medical advice. Tolcylen® CBD/CBG cream is not an FDA-approved drug and is not intended to diagnose, treat, cure, or prevent any disease.
